Profile of Dr Jayme Dahlin
Jayme Dahlin is currently a preclinical medicine and high-throughput biology consultant at the National Center for Advancing Translational Sciences (NCATS). Dr. Dahlin completed a residency in Clinical Pathology at Brigham and Women’s Hospital/Harvard Medical School and a postdoctoral fellowship in chemical biology in the laboratory of Stuart L. Schreiber at the Broad Institute. He graduated from Carleton College with a BA in chemistry, an M.D. from the Mayo Clinic, and a Ph.D. in Molecular Pharmacology and Experimental Therapeutics from Mayo Graduate School. Dr. Dahlin is board-certified by the American Board of Pathology. He has over 50 publications primarily focused on compound-dependent interferences and assay development. He serves on the editorial board of the NIH/NCATS Assay Guidance Manual and the scientific advisory board of the Chemical Probes Portal. In his current role, Dr. Dahlin serves in the Office of Translational Medicine where he provides medical direction to various NCATS projects. He also serves as the high-throughput biology lead for the NCATS ASPIRE Initiative which seeks to integrate advances in automated chemistry, high-throughput biology, and AI/ML to more rapidly explore chemical space in preclinical drug discovery.